Surinabant

Drug Profile

Surinabant

Alternative Names: SR147778

Latest Information Update: 04 Nov 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class Amides; Drug withdrawal therapies; Obesity therapies; Piperidines; Pyrazoles; Smoking cessation therapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alcoholism; Obesity; Psychotic disorders; Smoking withdrawal

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Oct 2008 Discontinued - Phase-II for Smoking withdrawal in European Union (PO)
  • 07 Mar 2005 Phase-II clinical trials in Obesity in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top